Cargando…

Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action

In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in...

Descripción completa

Detalles Bibliográficos
Autores principales: Mühlethaler, Tobias, Milanos, Lampros, Ortega, Jose Antonio, Blum, Thorsten B., Gioia, Dario, Roy, Bibhas, Prota, Andrea E., Cavalli, Andrea, Steinmetz, Michel O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324959/
https://www.ncbi.nlm.nih.gov/pubmed/35404502
http://dx.doi.org/10.1002/anie.202204052
_version_ 1784756930782167040
author Mühlethaler, Tobias
Milanos, Lampros
Ortega, Jose Antonio
Blum, Thorsten B.
Gioia, Dario
Roy, Bibhas
Prota, Andrea E.
Cavalli, Andrea
Steinmetz, Michel O.
author_facet Mühlethaler, Tobias
Milanos, Lampros
Ortega, Jose Antonio
Blum, Thorsten B.
Gioia, Dario
Roy, Bibhas
Prota, Andrea E.
Cavalli, Andrea
Steinmetz, Michel O.
author_sort Mühlethaler, Tobias
collection PubMed
description In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in G2/M, induces cell death, and synergizes with vinblastine. The compound destabilizes microtubules by acting as a molecular plug that sterically inhibits the curved‐to‐straight conformational switch in the α‐tubulin subunit, and by sequestering tubulin dimers into assembly incompetent oligomers. Our results describe for the first time the generation of a fully rationally designed small molecule tubulin inhibitor from a fragment, which displays a unique molecular mechanism of action. They thus demonstrate the usefulness of tubulin‐binding fragments as valuable starting points for innovative antitubulin drug and chemical probe discovery campaigns.
format Online
Article
Text
id pubmed-9324959
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93249592022-07-30 Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action Mühlethaler, Tobias Milanos, Lampros Ortega, Jose Antonio Blum, Thorsten B. Gioia, Dario Roy, Bibhas Prota, Andrea E. Cavalli, Andrea Steinmetz, Michel O. Angew Chem Int Ed Engl Research Articles In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in G2/M, induces cell death, and synergizes with vinblastine. The compound destabilizes microtubules by acting as a molecular plug that sterically inhibits the curved‐to‐straight conformational switch in the α‐tubulin subunit, and by sequestering tubulin dimers into assembly incompetent oligomers. Our results describe for the first time the generation of a fully rationally designed small molecule tubulin inhibitor from a fragment, which displays a unique molecular mechanism of action. They thus demonstrate the usefulness of tubulin‐binding fragments as valuable starting points for innovative antitubulin drug and chemical probe discovery campaigns. John Wiley and Sons Inc. 2022-04-25 2022-06-20 /pmc/articles/PMC9324959/ /pubmed/35404502 http://dx.doi.org/10.1002/anie.202204052 Text en © 2022 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Mühlethaler, Tobias
Milanos, Lampros
Ortega, Jose Antonio
Blum, Thorsten B.
Gioia, Dario
Roy, Bibhas
Prota, Andrea E.
Cavalli, Andrea
Steinmetz, Michel O.
Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action
title Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action
title_full Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action
title_fullStr Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action
title_full_unstemmed Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action
title_short Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action
title_sort rational design of a novel tubulin inhibitor with a unique mechanism of action
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324959/
https://www.ncbi.nlm.nih.gov/pubmed/35404502
http://dx.doi.org/10.1002/anie.202204052
work_keys_str_mv AT muhlethalertobias rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction
AT milanoslampros rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction
AT ortegajoseantonio rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction
AT blumthorstenb rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction
AT gioiadario rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction
AT roybibhas rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction
AT protaandreae rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction
AT cavalliandrea rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction
AT steinmetzmichelo rationaldesignofanoveltubulininhibitorwithauniquemechanismofaction